Nabitaka VM, Nawaggi P, Campbell J, Conroy J, et al. High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: A mixed-methods prospective cohort study. PLoS One 2020;15:e0232419.
PMID: 32459822